In general, the therapeutic rationale of PARP inhibitors relies on synthetic lethality associated with tumor-acquired mutations, most commonly defects in homologous recombination (HR) repair pathways, such as BRCA1/2 mutations. This evidence concerns the gene PARP1 and neoplasm.